In experimental transplantation, blockade of CD40-CD40 ligand (CD40L) interactions has proved effective at permitting long-term graft survival and has recently been approved for clinical evaluation. We show that CD4+ T cell-mediated rejection is prevented by anti-CD40L mAb therapy but that CD8+ T cells remain fully functional. Furthermore, blocking CD40L interactions has no effect on CD8+ T cell activation, proliferation, differentiation, homing to the target allograft, or cytokine production...Expand abstract
- Publication status:
- Publisher copy:
- Copyright date:
CD40-CD40 ligand-independent activation of CD8+ T cells can trigger allograft rejection.
If you are the owner of this record, you can report an update to it here: Report update to this record